Hematopoietic stem cell heterogeneity is linked to the initiation and therapeutic response of myeloproliferative neoplasms. (2021)
Attributed to:
Joint Wellcome and MRC Centre, ‘Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute’
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.stem.2021.02.026
PubMed Identifier: 33798424
Publication URI: http://europepmc.org/abstract/MED/33798424
Type: Journal Article/Review
Volume: 28
Parent Publication: Cell stem cell
Issue: 4
ISSN: 1875-9777